BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24867287)

  • 21. The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab.
    Forero-Castro M; Robledo C; Lumbreras E; Benito R; Hernández-Sánchez JM; Hernández-Sánchez M; García JL; Corchete-Sánchez LA; Tormo M; Barba P; Menárguez J; Ribera J; Grande C; Escoda L; Olivier C; Carrillo E; García de Coca A; Ribera JM; Hernández-Rivas JM
    Br J Haematol; 2016 Feb; 172(3):428-38. PubMed ID: 26567765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinicopathological characteristics of Burkitt lymphoma].
    Ohnishi K
    Nihon Rinsho; 2000 Mar; 58(3):635-8. PubMed ID: 10741137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathologic findings in high-grade B-cell lymphomas with typical Burkitt morphologic features but lacking the MYC translocation.
    Sevilla DW; Gong JZ; Goodman BK; Buckley PJ; Rosoff P; Gockerman JP; Lagoo AS
    Am J Clin Pathol; 2007 Dec; 128(6):981-91. PubMed ID: 18024324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of genomic aberrations suggest that Burkitt lymphomas with complex karyotype are distinct from other aggressive B-cell lymphomas with MYC rearrangement.
    Havelange V; Ameye G; Théate I; Callet-Bauchu E; Mugneret F; Michaux L; Dastugue N; Penther D; Barin C; Collonge-Rame MA; Baranger L; Terré C; Nadal N; Lippert E; Laï JL; Cabrol C; Tigaud I; Herens C; Hagemeijer A; Raphael M; Libouton JM; Poirel HA;
    Genes Chromosomes Cancer; 2013 Jan; 52(1):81-92. PubMed ID: 23012230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncogenic mechanisms in Burkitt lymphoma.
    Schmitz R; Ceribelli M; Pittaluga S; Wright G; Staudt LM
    Cold Spring Harb Perspect Med; 2014 Feb; 4(2):. PubMed ID: 24492847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells.
    Sampson VB; Rong NH; Han J; Yang Q; Aris V; Soteropoulos P; Petrelli NJ; Dunn SP; Krueger LJ
    Cancer Res; 2007 Oct; 67(20):9762-70. PubMed ID: 17942906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epstein-Barr virus and Burkitt's lymphoma.
    Magrath I; Jain V; Bhatia K
    Semin Cancer Biol; 1992 Oct; 3(5):285-95. PubMed ID: 1335792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.
    Williams SA; Chang L; Buzby JS; Suen Y; Cairo MS
    Leukemia; 1996 Dec; 10(12):1980-9. PubMed ID: 8946941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MiRNA profiling in B non-Hodgkin lymphoma: a MYC-related miRNA profile characterizes Burkitt lymphoma.
    Robertus JL; Kluiver J; Weggemans C; Harms G; Reijmers RM; Swart Y; Kok K; Rosati S; Schuuring E; van Imhoff G; Pals ST; Kluin P; van den Berg A
    Br J Haematol; 2010 Jun; 149(6):896-9. PubMed ID: 20331457
    [No Abstract]   [Full Text] [Related]  

  • 30. Epstein-Barr virus and Burkitt lymphoma.
    Brady G; Macarthur GJ; Farrell PJ
    Postgrad Med J; 2008 Jul; 84(993):372-7. PubMed ID: 18716017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transformation of follicular lymphoma to Burkitt-like lymphoma within a single lymph node.
    Mukhopadhyay S; Readling J; Cotter PD; Shrimpton AE; Sidhu JS
    Hum Pathol; 2005 May; 36(5):571-5. PubMed ID: 15948125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach.
    Bellan C; Stefano L; Giulia de F; Rogena EA; Lorenzo L
    Hematol Oncol; 2010 Jun; 28(2):53-6. PubMed ID: 19844983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in the understanding of MYC-induced lymphomagenesis.
    Klapproth K; Wirth T
    Br J Haematol; 2010 May; 149(4):484-97. PubMed ID: 20346013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.
    Hummel M; Bentink S; Berger H; Klapper W; Wessendorf S; Barth TF; Bernd HW; Cogliatti SB; Dierlamm J; Feller AC; Hansmann ML; Haralambieva E; Harder L; Hasenclever D; Kühn M; Lenze D; Lichter P; Martin-Subero JI; Möller P; Müller-Hermelink HK; Ott G; Parwaresch RM; Pott C; Rosenwald A; Rosolowski M; Schwaenen C; Stürzenhofecker B; Szczepanowski M; Trautmann H; Wacker HH; Spang R; Loeffler M; Trümper L; Stein H; Siebert R;
    N Engl J Med; 2006 Jun; 354(23):2419-30. PubMed ID: 16760442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53.
    Ramqvist T; Magnusson KP; Wang Y; Szekely L; Klein G; Wiman KG
    Oncogene; 1993 Jun; 8(6):1495-500. PubMed ID: 8502475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular heterogeneity of sporadic adult Burkitt-type leukemia/lymphoma as revealed by PCR and cytogenetics: correlation with morphology, immunology and clinical features.
    Burmeister T; Schwartz S; Horst HA; Rieder H; Gökbuget N; Hoelzer D; Thiel E
    Leukemia; 2005 Aug; 19(8):1391-8. PubMed ID: 15973450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular switch from MYC to MYCN expression in MYC protein negative Burkitt lymphoma cases.
    Mundo L; Ambrosio MR; Raimondi F; Del Porro L; Guazzo R; Mancini V; Granai M; Jim Rocca B; Lopez C; Bens S; Onyango N; Nyagol J; Abinya N; Navari M; Ndede I; Patel K; Paolo Piccaluga P; Bob R; de Santi MM; Russell RB; Lazzi S; Siebert R; Stein H; Leoncini L
    Blood Cancer J; 2019 Nov; 9(12):91. PubMed ID: 31748534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clustered mutations in the second exon of the MYC gene in sporadic Burkitt's lymphoma.
    Yano T; Sander CA; Clark HM; Dolezal MV; Jaffe ES; Raffeld M
    Oncogene; 1993 Oct; 8(10):2741-8. PubMed ID: 8397370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cutaneous involvement with Burkitt-like lymphoma.
    Pettey AA; Walsh JS
    Am J Dermatopathol; 2007 Apr; 29(2):184-6. PubMed ID: 17414444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recurrent RHOA mutations in pediatric Burkitt lymphoma treated according to the NHL-BFM protocols.
    Rohde M; Richter J; Schlesner M; Betts MJ; Claviez A; Bonn BR; Zimmermann M; Damm-Welk C; Russell RB; Borkhardt A; Eils R; Hoell JI; Szczepanowski M; Oschlies I; Klapper W; Burkhardt B; Siebert R; ;
    Genes Chromosomes Cancer; 2014 Nov; 53(11):911-6. PubMed ID: 25044415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.